Ranbaxy Lab and Daiichi Sankyo to launch Olmesartan medoxomil

02 Aug 2011 Evaluate

Ranbaxy Laboratories and Daiichi Sankyo Company have agreed to expand the group’s business in Mexico with the launch of Olmesartan medoxomil. The product is expected to be introduced in the market before the end of 2011.

Daiichi Sankyo Mexico  S.A de C.V (DSMX), newly established  subsidiary of Daiichi Sankyo, and Ranbaxy Mexico  S.A de C.V (RMEX) subsidiary of Ranbaxy will leverage the group’s hybrid business model in Mexico by utilizing the business know how  and cost advantage of Ranbaxy, thereby offering both innovative and affordable, high quality generic medicines.

Olmesartan medoxomil is a member of the angiontensin receptor blocker (ARB) class of antihypertensive medications that helps lower blood pressure by blocking the agniotensin II receptor on the blood vessels and antagonizing the release of the hormone which causes salt retention and increased blood volume.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1267.15
Cipla 1498.90
Zydus Lifesciences 924.35
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×